相关实验视频
Updated: May 7, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.9K
在不影响血静参数的情况下抑制动脉血栓形成,使用细胞透的PAR1
Ping Zhang1, András Gruber, Shogo Kasuda
1Hemostasis & Thrombosis Laboratory, Tufts Medical Center, Box 7510, 750 Washington St, Boston, MA 02111, USA.
Circulation
|June 19, 2012
概括
一种新型的PAR1抑制剂PZ-128在穿皮冠状动脉干预期间有效降低血小板激活和血栓形成,而不会影响血静. 这种新疗法为急性冠状动脉综合征提供了快速,可逆的血小板抑制.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 血栓形成研究研究
背景情况:
- 穿皮冠状动脉干预 (PCI) 增加了对血栓依赖的血小板激活,增加了急性冠状动脉综合征中的动脉血栓形成风险和心肌亡.
- 现有的治疗方法面临着副作用的挑战,突出了针对血小板激活的新型治疗方法的需要,同时保持血静.
- 蛋白酶激活受体1 (PAR1) 是血栓信号传递的关键媒介,也是抗血小板治疗的新兴标.
研究的目的:
- 开发和表征一种第一类的细胞内PAR1抑制剂 (PZ-128) 用于PCI.
- 在临床前模型中评估PZ-128的药理动力学特性,疗效和安全性.
主要方法:
- 开发PZ-128,一种透细胞的杜辛,向PAR1受体-G蛋白界面.
- 评估PZ-128的快速发病,抑制血小板聚合,以及对几内亚猪和的抗血栓作用.
- 评估PZ-128对灵长类动物和人类血液样本出血和凝血参数的影响.
主要成果:
- 在体内,PZ-128表现出迅速开始作用,抑制了PAR1介导的血小板聚合和动脉血栓形成.
- 该抑制剂与克洛皮多格雷尔具有强烈的协同作用,并在24小时内完全恢复了血小板功能.
- 最重要的是,PZ-128没有影响灵长类动物或人类血液的出血或凝血参数,这表明了有利的安全性.
结论:
- PZ-128表现出强烈的抗血小板活性,具有快速发作和可逆效果,适合急性PCI设置.
- 缺乏对血静的不良影响表明,PZ-128可能会为现有的PAR1抑制剂提供更安全的替代品.
- PZ-128是治疗急性冠状动脉综合征PCI患者血小板激活的有希望的候选药物.
相关概念视频
Paracrine Signaling
50.3K
Paracrine signaling allows cells to communicate with their immediate neighbors via secretion of signaling molecules. Such a signal can only trigger a response in nearby target cells because the signal molecules degrade quickly or are inactivated if not taken up. Prominent examples of paracrine signaling include nitric oxide signaling in blood vessels, synaptic signaling of neurons, the blood clotting system, tissue repair/wound healing, and local allergic skin reactions. Nitric oxide as a...
50.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
618
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618
Inhibitors of Gram-positive Cell Wall Synthesis
225
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
225

